TABLE 3.
Antiviral activities against wild-type and IN mutant RSVa
| Virus | RALb |
EVGb |
AZTb |
|||
|---|---|---|---|---|---|---|
| EC50 (μM) | EC95 (μM) | EC50 (μM) | EC95 (μM) | EC50 (μM) | EC95 (μM) | |
| RSV | 0.15 ± 0.03 | 7.2 ± 0.3 | 7.2 ± 0.3 | >10 | 0.036 ± 0.006 | 0.66 ± 0.0004 |
| G152S mutant | 0.85 ± 0.23 (5.7) | 9.2 ± 0.2 (1.3) | 7.7 ± 1.1 (1.1) | >10 (>1.0) | 0.031 ± 0.002 (0.9) | 0.55 ± 0.08 (0.8) |
| S150P mutant | 0.29 ± 0.04 (1.9) | 8.9 ± 0.8 (1.2) | 0.098 ± 0.014 (0.01) | 5.0 ± 0.4 (<0.5) | 0.037 ± 0.004 (1.0) | 0.67 ± 0.03 (1.0) |
| S150P/G152S mutant | 0.64 ± 0.30 (4.3) | 9.4 ± 1.0 (1.3) | 0.19 ± 0.03 (0.03) | >10 (>1.0) | 0.036 ± 0.002 (1.0) | 0.65 ± 0.01 (1.0) |
a
Means ± standard deviations of three independent experiments, each conducted in duplicate.
b
The FC in EC50 or EC95 relative to that of the wild-type is indicated in parentheses.